Injectable semaglutide has a very high bioavailability of around 89%
The most commonly reported GI AEs include nausea, diarrhoea, vomiting, and constipation, which are typically mild to moderate in intensity and transient in duration [13, 38, 40,41,42,43,44,45,46, 52]
The most effective GLP-1 strategies offer patients multiple pathways, giving them access to medication, lifestyle interventions, and sustainable off-ramps based on their individual needs
Moreover, ouabain can modulate epithelial cell tight junctions through ERK1/2 and c-Src signaling pathways (Rajasekaran et al
Patients with certain medical conditions, such as gastrointestinal issues (e.g., gastroparesis) or a history of pancreatitis, may not be good candidates for GLP-1 treatment
The best wellness plan is personalized